Physician profile
Joel C Webb
NPI 1306871462
$4,809.53
in general payments reported to CMS, 2019-2025
27 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $14.18 · 2021: $860 · 2022: $686 · 2023: $514 · 2024: $1,128 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.40 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $956.81 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Stryker Corporation | $800.62 | 2021-2025 | 1788 |
| Genmab U.S., INC. | $544.63 | 2021-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $412.26 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $394.84 | 2022-2025 | Jemperli, Zejula |
| Eisai INC. | $276.07 | 2021-2025 | |
| Seagen INC. | $198.99 | 2024-2025 | |
| Tempus Ai, INC | $160.20 | 2025 | Xt Cdx |
| Genentech USA, INC. | $136.18 | 2019-2024 | Phesgo, Perjeta, Herceptin |
| Tesaro, INC. | $120.34 | 2019 | |
| Astellas Pharma US INC | $117.22 | 2024-2025 | Veozah |
| Medtronic, INC. | $94.95 | 2024 | Synchromedii |
| Abbvie INC. | $94.91 | 2019-2025 | |
| Intuitive Surgical, INC. | $86.11 | 2019 | |
| Amgen INC. | $77.44 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| On Target Laboratories, INC | $76.60 | 2025 | Cytalux |
| Daiichi Sankyo INC. | $42.67 | 2023 | Enhertu |
| Amneal Pharmaceuticals LLC | $38.96 | 2023 | Neulasta, Avastin, Neupogen |
| Celltrion USA INC. | $35.54 | 2023-2024 | Vegzelma |
| Pharmaand Gmbh | $26.15 | 2025 | Rubraca |
| Clovis Oncology, INC. | $25.71 | 2019-2021 | |
| Ethicon US, LLC | $24.51 | 2024 | Stratafix |
| Aspira Women'S Health INC | $16.38 | 2019 | |
| Avion Pharmaceuticals | $15.63 | 2022 | |
| Lilly USA, LLC | $12.16 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.99 | 2019 | |
| Myriad Genetic Laboratories, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.